Cyclerion Therapeutics Inc
CYCN1.380USD
-0.050-3.50%
Close 12/24, 13:00（ET）Quotes delayed by 15 min
5.10MMarket Cap
LossP/E TTM
More Details of Cyclerion Therapeutics Inc Company
Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to identifying, developing, and delivering therapies for central nervous system (CNS) diseases. The Company is focused on building a pipeline with therapeutics to treat certain neuropsychiatric diseases. It is focused on an individualized therapy for treatment-resistant depression (TRD) - a condition with significant unmet medical need. Its assets include Olinciguat and Praliciguat. The Company has entered into an exclusive license option agreement for its vascular soluble guanylate cyclase (sGC) stimulator, olinciguat. Praliciguat is an oral, once-daily, systemic sGC stimulator that is licensed to Akeibia Therapeutics, Inc and is being advanced in rare kidney disease.
Cyclerion Therapeutics Inc Info
Ticker SymbolCYCN
Company nameCyclerion Therapeutics Inc
IPO dateMar 18, 2019
CEOGraul (Regina M)
Number of employees1
Security typeOrdinary Share
Fiscal year-endMar 18
Address301 Binney Street
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02142
Phone16176217722
Websitehttps://www.cyclerion.com/
Ticker SymbolCYCN
IPO dateMar 18, 2019
CEOGraul (Regina M)
Company Executives of Cyclerion Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Peter M. Hecht, Ph.D.
Dr. Peter M. Hecht, Ph.D.
Director
Director
559.20K
--
Dr. Errol B. De Souza, Ph.D.
Dr. Errol B. De Souza, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
50.00K
--
Mr. Michael J. Higgins
Mr. Michael J. Higgins
Independent Director
Independent Director
30.74K
+5.67%
Dr. Dina Katabi, Ph.D.
Dr. Dina Katabi, Ph.D.
Independent Director
Independent Director
20.00K
--
Dr. Regina M. Graul, Ph.D.
Dr. Regina M. Graul, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Rhonda M. Chicko
Ms. Rhonda M. Chicko
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Steven E. Hyman, M.D.
Dr. Steven E. Hyman, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Peter M. Hecht, Ph.D.
Dr. Peter M. Hecht, Ph.D.
Director
Director
559.20K
--
Dr. Errol B. De Souza, Ph.D.
Dr. Errol B. De Souza, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
50.00K
--
Mr. Michael J. Higgins
Mr. Michael J. Higgins
Independent Director
Independent Director
30.74K
+5.67%
Dr. Dina Katabi, Ph.D.
Dr. Dina Katabi, Ph.D.
Independent Director
Independent Director
20.00K
--
Dr. Regina M. Graul, Ph.D.
Dr. Regina M. Graul, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Rhonda M. Chicko
Ms. Rhonda M. Chicko
Chief Financial Officer
Chief Financial Officer
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Hecht (Peter M)
14.25%
J. Wood Capital Advisors LLC
4.63%
American Endowment Foundation
3.39%
Invus Public Equities Advisors, LLC
2.96%
Graul (Regina Margaret)
1.42%
Other
73.35%
Shareholders
Shareholders
Proportion
Hecht (Peter M)
14.25%
J. Wood Capital Advisors LLC
4.63%
American Endowment Foundation
3.39%
Invus Public Equities Advisors, LLC
2.96%
Graul (Regina Margaret)
1.42%
Other
73.35%
Shareholder Types
Shareholders
Proportion
Individual Investor
18.74%
Corporation
8.02%
Investment Advisor
5.70%
Investment Advisor/Hedge Fund
0.95%
Hedge Fund
0.40%
Research Firm
0.02%
Other
66.16%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
33
277.64K
23.79%
--
2025Q3
36
277.64K
28.05%
-103.98K
2025Q2
36
381.62K
29.96%
-10.58K
2025Q1
53
392.20K
30.91%
-599.93K
2024Q4
57
398.50K
41.58%
-660.57K
2024Q3
62
1.11M
44.54%
-7.58K
2024Q2
66
1.10M
44.98%
-18.58K
2024Q1
76
1.12M
48.61%
-196.27K
2023Q4
83
1.12M
54.12%
-3.34K
2023Q3
98
1.12M
59.61%
-44.82K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Hecht (Peter M)
559.20K
16.76%
--
--
Apr 21, 2025
J. Wood Capital Advisors LLC
181.82K
5.45%
+181.82K
--
Apr 21, 2025
American Endowment Foundation
133.03K
3.99%
+133.03K
--
Dec 31, 2024
Invus Public Equities Advisors, LLC
116.16K
3.48%
--
--
Jun 30, 2025
Graul (Regina Margaret)
55.78K
1.67%
-44.52K
-44.39%
Apr 21, 2025
De Souza (Errol B)
50.00K
1.5%
--
--
Apr 21, 2025
Geode Capital Management, L.L.C.
32.73K
0.98%
+1.13K
+3.58%
Jun 30, 2025
Higgins (Michael J)
30.74K
0.92%
+1.65K
+5.67%
Apr 21, 2025
The Vanguard Group, Inc.
23.49K
0.7%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Fidelity Nasdaq Composite Index ETF
0%
Fidelity Nasdaq Composite Index ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
Date
Type
Ratio
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
May 15, 2023
Merger
20→1
FAQs
Who are the top five shareholders of Cyclerion Therapeutics Inc?
The top five shareholders of Cyclerion Therapeutics Inc are:
Hecht (Peter M) holds 559.20K shares, accounting for 16.76% of the total shares.
J. Wood Capital Advisors LLC holds 181.82K shares, accounting for 5.45% of the total shares.
American Endowment Foundation holds 133.03K shares, accounting for 3.99% of the total shares.
Invus Public Equities Advisors, LLC holds 116.16K shares, accounting for 3.48% of the total shares.
Graul (Regina Margaret) holds 55.78K shares, accounting for 1.67% of the total shares.
Hecht (Peter M) holds 559.20K shares, accounting for 16.76% of the total shares.
J. Wood Capital Advisors LLC holds 181.82K shares, accounting for 5.45% of the total shares.
American Endowment Foundation holds 133.03K shares, accounting for 3.99% of the total shares.
Invus Public Equities Advisors, LLC holds 116.16K shares, accounting for 3.48% of the total shares.
Graul (Regina Margaret) holds 55.78K shares, accounting for 1.67% of the total shares.
What are the top three shareholder types of Cyclerion Therapeutics Inc?
The top three shareholder types of Cyclerion Therapeutics Inc are:
Hecht (Peter M)
J. Wood Capital Advisors LLC
American Endowment Foundation
Hecht (Peter M)
J. Wood Capital Advisors LLC
American Endowment Foundation
How many institutions hold shares of Cyclerion Therapeutics Inc (CYCN)?
As of 2025Q4, 33 institutions hold shares of Cyclerion Therapeutics Inc, with a combined market value of approximately 277.64K, accounting for 23.79% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -4.26%.
What is the biggest source of revenue for Cyclerion Therapeutics Inc?
In --, the -- business generated the highest revenue for Cyclerion Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
